American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Association; 2013.
The Tourette Syndrome Classification Study Group. Definitions and classification of tic disorders. Arch Neurol. 1993 Oct. 50(10):1013-6. [QxMD MEDLINE Link].
Tamara P. Tourette syndrome and other tic disorders of childhood. Handb Clin Neurol. 2013. 112:853-6. [QxMD MEDLINE Link].
Ludolph AG, Roessner V, Münchau A, Müller-Vahl K. Tourette syndrome and other tic disorders in childhood, adolescence and adulthood. Dtsch Arztebl Int. 2012 Nov. 109(48):821-288. [QxMD MEDLINE Link]. [Full Text].
American Psychiatric Association. Obsessive-Compulsive and Related Disorders. In: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 5th ed. Arlington, Va: American Psychiatric Association; 2013.
McHenry LC Jr. Samuel Johnson's tics and gesticulations. J Hist Med Allied Sci. 1967 Apr. 22(2):152-68. [QxMD MEDLINE Link].
Murray TJ. Dr Samuel Johnson's movement disorder. Br Med J. 1979 Jun 16. 1(6178):1610-4. [QxMD MEDLINE Link]. [Full Text].
Kushner HI. A Cursing Brain--The Histories of Tourette Syndrome. Cambridge, MA: Harvard University Press;. 1999.
Gilles de la Tourette G. Etude sur une Affection Nerveuse Caracterisee par de l'Incoordination Motrice Accompagnee d'Echolalie et de Coprolalie. Archives de Neurologie. 1885. 9:19-42, 158-200.
Miller AM, Bansal R, Hao X, Sanchez-Pena JP, Sobel LJ, Liu J. Enlargement of thalamic nuclei in Tourette syndrome. Arch Gen Psychiatry. 2010 Sep. 67(9):955-64. [QxMD MEDLINE Link].
Kurlan R, Goetz CG, McDermott MP. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002 Feb 26. 58(4):527-36. [QxMD MEDLINE Link].
Comings DE. Blood serotonin and tryptophan in Tourette syndrome. Am J Med Genet. 1990 Aug. 36(4):418-30. [QxMD MEDLINE Link].
Comings DE, Gade R, Muhleman D, et al. Exon and intron variants in the human tryptophan 2,3-dioxygenase gene: potential association with Tourette syndrome, substance abuse and other disorders. Pharmacogenetics. 1996 Aug. 6(4):307-18. [QxMD MEDLINE Link].
Muller-Vahl KR, Meyer GJ, Knapp WH, et al. Serotonin transporter binding in Tourette Syndrome. Neurosci Lett. 2005 Sep 9. 385(2):120-5. [QxMD MEDLINE Link].
Niesler B, Frank B, Hebebrand J, et al. Serotonin receptor genes HTR3A and HTR3B are not involved in Gilles de la Tourette syndrome. Psychiatr Genet. 2005 Dec. 15(4):303-4. [QxMD MEDLINE Link].
Toren P, Weizman A, Ratner S, et al. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2005 Apr. 66(4):499-503. [QxMD MEDLINE Link].
Muller-Vahl KR. Cannabinoids reduce symptoms of Tourette''s syndrome. Expert Opin Pharmacother. 2003 Oct. 4(10):1717-25. [QxMD MEDLINE Link].
McGrath MJ, Campbell KM, Parks CR, Burton FH. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette''s syndrome and obsessive-compulsive disorder. Brain Res. 2000 Sep 15. 877(1):23-30. [QxMD MEDLINE Link].
van Wattum PJ, Anderson GM, Chappell PB, et al. Cerebrospinal fluid dynorphin A[1-8] and beta-endorphin levels in Tourette''s syndrome are unaltered. Biol Psychiatry. 1999 Jun 1. 45(11):1527-8. [QxMD MEDLINE Link].
Weeks RA, Lees AJ, Brooks DJ. Tourette''s syndrome and the opioid system. Lancet. 1994 Apr 30. 343(8905):1107-8. [QxMD MEDLINE Link].
Kumar R, Lang AE. Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis. Neurology. 1997 Dec. 49(6):1699-701. [QxMD MEDLINE Link].
Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson''s disease. Brain. 1999 Aug. 122 (Pt 8):1437-48. [QxMD MEDLINE Link].
Black KJ, Mink JW. Response to levodopa challenge in Tourette syndrome. Mov Disord. 2000 Nov. 15(6):1194-8. [QxMD MEDLINE Link].
Gilbert DL, Sallee FR, Sine L. Behavioral and hormonal effects of low-dose pergolide in children and adolescents with Gilles de la Tourette's syndrome. Curr Ther Res Clin Exp. 2000. 61:378.
Gilbert DL, Dure L, Sethuraman G, et al. Tic reduction with pergolide in a randomized controlled trial in children. Neurology. 2003 Feb 25. 60(4):606-11. [QxMD MEDLINE Link].
Diaz-Anzaldua A, Joober R, Riviere JB, et al. Tourette syndrome and dopaminergic genes: a family-based association study in the French Canadian founder population. Mol Psychiatry. 2004 Mar. 9(3):272-7. [QxMD MEDLINE Link].
Lee CC, Chou IC, Tsai CH, et al. Dopamine receptor D2 gene polymorphisms are associated in Taiwanese children with Tourette syndrome. Pediatr Neurol. 2005 Oct. 33(4):272-6. [QxMD MEDLINE Link].
Heinz A, Knable MB, Wolf SS, et al. Tourette''s syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology. 1998 Oct. 51(4):1069-74. [QxMD MEDLINE Link].
Singer HS, Wong DF, Brown JE, et al. Positron emission tomography evaluation of dopamine D-2 receptors in adults with Tourette syndrome. Adv Neurol. 1992. 58:233-9. [QxMD MEDLINE Link].
Turjanski N, Sawle GV, Playford ED, et al. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette''s syndrome. J Neurol Neurosurg Psychiatry. 1994 Jun. 57(6):688-92. [QxMD MEDLINE Link].
Wong DF, Singer HS, Brandt J, et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med. 1997 Aug. 38(8):1243-7. [QxMD MEDLINE Link].
Wolf SS, Jones DW, Knable MB, et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 1996 Aug 30. 273(5279):1225-7. [QxMD MEDLINE Link].
Robertson MM. D2 be or not to be?. Nat Med. 1996 Oct. 2(10):1076-7. [QxMD MEDLINE Link].
Albin RL, Koeppe RA, Bohnen NI, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology. 2003 Aug 12. 61(3):310-5. [QxMD MEDLINE Link]. [Full Text].
Ernst M, Zametkin AJ, Jons PH, et al. High presynaptic dopaminergic activity in children with Tourette''s disorder. J Am Acad Child Adolesc Psychiatry. 1999 Jan. 38(1):86-94. [QxMD MEDLINE Link].
Malison RT, McDougle CJ, van Dyck CH, et al. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette''s disorder. Am J Psychiatry. 1995 Sep. 152(9):1359-61. [QxMD MEDLINE Link].
Meyer P, Bohnen NI, Minoshima S, et al. Striatal presynaptic monoaminergic vesicles are not increased in Tourette''s syndrome. Neurology. 1999 Jul 22. 53(2):371-4. [QxMD MEDLINE Link].
Peterson BS. Neuroimaging studies of Tourette syndrome: a decade of progress. In: Cohen DJ, Jankovic J, Goetz CG, eds. Tourette Syndrome. Philadelphia: Lippincott Williams & Wilkins. 2001:179-96.
Serra-Mestres J, Ring HA, Costa DC, et al. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Acta Psychiatr Scand. 2004 Feb. 109(2):140-6. [QxMD MEDLINE Link].
Singer HS, Szymanski S, Giuliano J, et al. Elevated intrasynaptic dopamine release in Tourette''s syndrome measured by PET. Am J Psychiatry. 2002 Aug. 159(8):1329-36. [QxMD MEDLINE Link].
Stamenkovic M, Schindler SD, Asenbaum S, et al. No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette''s disorder patients: a [(123)I]-beta-CIT SPECt-study. Eur Neuropsychopharmacol. 2001 Feb. 11(1):69-74. [QxMD MEDLINE Link].
Wong D, Singer H, Marenco S. Dopamine transporter reuptake sites measured by [11C]WIN 35,428 PET imaging are elevated in Tourette syndrome. J Nucl Med. 1994. 35:130.
Cheon KA, Ryu YH, Namkoong K, et al. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Res. 2004 Jan 15. 130(1):85-95. [QxMD MEDLINE Link].
Black KJ, Hershey T, Akbudak E, et al. Levodopa activation pharmacologic fMRI in Tourette syndrome. Abstract presented at: 34th Annual Meeting of the Society for Neuroscience. October 23-27, 2004;. San Diego, CA. [Full Text].
Channon S, Sinclair E, Waller D, et al. Social cognition in Tourette''s syndrome: intact theory of mind and impaired inhibitory functioning. J Autism Dev Disord. 2004 Dec. 34(6):669-77. [QxMD MEDLINE Link].
Goudriaan AE, Oosterlaan J, de Beurs E, et al. Decision making in pathological gambling: a comparison between pathological gamblers, alcohol dependents, persons with Tourette syndrome, and normal controls. Brain Res Cogn Brain Res. 2005 Apr. 23(1):137-51. [QxMD MEDLINE Link].
Serrien DJ, Orth M, Evans AH, et al. Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence. Brain. 2005 Jan. 128(Pt 1):116-25. [QxMD MEDLINE Link].
Hershey T, Black KJ, Hartlein J, Braver TS, Barch DM, Carl JL, et al. Dopaminergic modulation of response inhibition: an fMRI study. Brain Res Cogn Brain Res. 2004 Aug. 20(3):438-48. [QxMD MEDLINE Link].
Braun AR, Stoetter B, Randolph C, et al. The functional neuroanatomy of Tourette''s syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology. 1993 Dec. 9(4):277-91. [QxMD MEDLINE Link].
Diler RS, Reyhanli M, Toros F, Kibar M, Avci A. Tc-99m-ECD SPECT brain imaging in children with Tourette's syndrome. Yonsei Med J. 2002 Aug. 43(4):403-10. [QxMD MEDLINE Link].
George MS, Trimble MR, Costa DC, et al. Elevated frontal cerebral blood flow in Gilles de la Tourette syndrome: a 99Tcm-HMPAO SPECT study. Psychiatry Res. 1992 Nov. 45(3):143-51. [QxMD MEDLINE Link].
Hall M, Costa DC, Shields J, et al. Brain perfusion patterns with Tc-99m-HMPAO/SPET in patients with Gilles de la Tourette syndrome. Eur J Nucl Med. 1990. 16:WP18.
Klieger PS, Fett KA, Dimitsopulos T, Karlan R. Asymmetry of basal ganglia perfusion in Tourette''s syndrome shown by technetium-99m-HMPAO SPECT. J Nucl Med. 1997 Feb. 38(2):188-91. [QxMD MEDLINE Link].
Moriarty J, Costa DC, Schmitz B, et al. Brain perfusion abnormalities in Gilles de la Tourette''s syndrome. Br J Psychiatry. 1995 Aug. 167(2):249-54. [QxMD MEDLINE Link].
Riddle MA, Rasmusson AM, Woods SW, Hoffer PB. SPECT imaging of cerebral blood flow in Tourette syndrome. Adv Neurol. 1992. 58:207-11. [QxMD MEDLINE Link].
Braun AR, Randolph C, Stoetter B, et al. The functional neuroanatomy of Tourette''s syndrome: an FDG-PET Study. II: Relationships between regional cerebral metabolism and associated behavioral and cognitive features of the illness. Neuropsychopharmacology. 1995 Oct. 13(2):151-68. [QxMD MEDLINE Link].
Crespo-Facorro B, Cabranes JA, Lopez-Ibor Alcocer MI, et al. Regional cerebral blood flow in obsessive-compulsive patients with and without a chronic tic disorder. A SPECT study. Eur Arch Psychiatry Clin Neurosci. 1999. 249(3):156-61. [QxMD MEDLINE Link].
Eidelberg D, Moeller JR, Kazumata K, Antonini A, Sterio D, Dhawan V, et al. Metabolic correlates of pallidal neuronal activity in Parkinson's disease. Brain. 1997 Aug. 120 ( Pt 8):1315-24. [QxMD MEDLINE Link].
Peterson BS, Skudlarski P, Anderson AW, et al. A functional magnetic resonance imaging study of tic suppression in Tourette syndrome. Arch Gen Psychiatry. 1998 Apr. 55(4):326-33. [QxMD MEDLINE Link].
Stern E, Silbersweig DA, Chee KY, et al. A functional neuroanatomy of tics in Tourette syndrome. Arch Gen Psychiatry. 2000 Aug. 57(8):741-8. [QxMD MEDLINE Link].
Jeffries KJ, Schooler C, Schoenbach C, et al. The functional neuroanatomy of Tourette''s syndrome: an FDG PET study III: functional coupling of regional cerebral metabolic rates. Neuropsychopharmacology. 2002 Jul. 27(1):92-104. [QxMD MEDLINE Link].
Gates L, Clarke JR, Stokes A, et al. Neuroanatomy of coprolalia in Tourette syndrome using functional magnetic resonance imaging. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar. 28(2):397-400. [QxMD MEDLINE Link].
Biswal B, Ulmer JL, Krippendorf RL, et al. Abnormal cerebral activation associated with a motor task in Tourette syndrome. AJNR Am J Neuroradiol. 1998 Sep. 19(8):1509-12. [QxMD MEDLINE Link].
Serrien DJ, Nirkko AC, Loher TJ, et al. Movement control of manipulative tasks in patients with Gilles de la Tourette syndrome. Brain. 2002 Feb. 125(Pt 2):290-300. [QxMD MEDLINE Link].
Rauch SL, Whalen PJ, Curran T, et al. Probing striato-thalamic function in obsessive-compulsive disorder and Tourette syndrome using neuroimaging methods. Adv Neurol. 2001. 85:207-24. [QxMD MEDLINE Link].
Swerdlow NR, Karban B, Ploum Y, et al. Tactile prepuff inhibition of startle in children with Tourette''s syndrome: in search of an "fMRI-friendly" startle paradigm. Biol Psychiatry. 2001 Oct 15. 50(8):578-85. [QxMD MEDLINE Link].
Laplane D, Widlocher D, Pillon B, et al. [Obsessional-type compulsive behavior caused by bilateral circumscribed pallidostriatal necrosis. Encephalopathy caused by a wasp sting]. Rev Neurol (Paris). 1981. 137(4):269-76. [QxMD MEDLINE Link].
Laplane D. [Obsessive-compulsive disorders caused by basal ganglia diseases]. Rev Neurol (Paris). 1994 Aug-Sep. 150(8-9):594-8. [QxMD MEDLINE Link].
Peterson BS, Staib L, Scahill L, et al. Regional brain and ventricular volumes in Tourette syndrome. Arch Gen Psychiatry. 2001 May. 58(5):427-40. [QxMD MEDLINE Link].
Peterson BS, Thomas P, Kane MJ, et al. Basal Ganglia volumes in patients with Gilles de la Tourette syndrome. Arch Gen Psychiatry. 2003 Apr. 60(4):415-24. [QxMD MEDLINE Link].
Eichele H, Plessen KJ. Neural plasticity in functional and anatomical MRI studies of children with Tourette syndrome. Behav Neurol. 2013. 27(1):33-45. [QxMD MEDLINE Link].
Bloch MH, Leckman JF, Zhu H, et al. Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome. Neurology. 2005 Oct 25. 65(8):1253-8. [QxMD MEDLINE Link].
Fredericksen KA, Cutting LE, Kates WR, et al. Disproportionate increases of white matter in right frontal lobe in Tourette syndrome. Neurology. 2002 Jan 8. 58(1):85-9. [QxMD MEDLINE Link].
Hong KE, Ock SM, Kang MH, et al. The segmented regional volumes of the cerebrum and cerebellum in boys with Tourette syndrome. J Korean Med Sci. 2002 Aug. 17(4):530-6. [QxMD MEDLINE Link].
Hyde TM, Stacey ME, Coppola R, et al. Cerebral morphometric abnormalities in Tourette''s syndrome: a quantitative MRI study of monozygotic twins. Neurology. 1995 Jun. 45(6):1176-82. [QxMD MEDLINE Link].
Peterson BS, Gore JC, Riddle MA, et al. Abnormal magnetic resonance imaging T2 relaxation time asymmetries in Tourette''s syndrome. Psychiatry Res. 1994 Dec. 55(4):205-21. [QxMD MEDLINE Link].
Giedd JN, Rapoport JL, Leonard HL, et al. Case study: acute basal ganglia enlargement and obsessive-compulsive symptoms in an adolescent boy. J Am Acad Child Adolesc Psychiatry. 1996 Jul. 35(7):913-5. [QxMD MEDLINE Link].
Castellanos FX, Giedd JN, Hamburger SD, et al. Brain morphometry in Tourette''s syndrome: the influence of comorbid attention-deficit/hyperactivity disorder. Neurology. 1996 Dec. 47(6):1581-3. [QxMD MEDLINE Link].
Peterson BS, Leckman JF, Tucker D, et al. Preliminary findings of antistreptococcal antibody titers and basal ganglia volumes in tic, obsessive-compulsive, and attention deficit/hyperactivity disorders. Arch Gen Psychiatry. 2000 Apr. 57(4):364-72. [QxMD MEDLINE Link].
Hallett M. Neurophysiology of tics. Adv Neurol. 2001. 85:237-44. [QxMD MEDLINE Link].
Johannes S, Wieringa BM, Nager W, et al. Tourette syndrome and obsessive-compulsive disorder: event-related brain potentials show similar mechanisms [correction of mechansims] of frontal inhibition but dissimilar target evaluation processes. Behav Neurol. 2003. 14(1-2):9-17. [QxMD MEDLINE Link].
Johannes S, Wieringa BM, Nager W, et al. Excessive action monitoring in Tourette syndrome. J Neurol. 2002 Aug. 249(8):961-6. [QxMD MEDLINE Link].
O''Connor K, Lavoie ME, Robert M. Preparation and motor potentials in chronic tic and Tourette syndromes. Brain Cogn. 2001 Jun-Jul. 46(1-2):224-6. [QxMD MEDLINE Link].
Ziemann U, Paulus W, Rothenberger A. Decreased motor inhibition in Tourette''s disorder: evidence from transcranial magnetic stimulation. Am J Psychiatry. 1997 Sep. 154(9):1277-84. [QxMD MEDLINE Link].
Moll GH, Heinrich H, Trott GE, et al. Children with comorbid attention-deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system. Ann Neurol. 2001 Mar. 49(3):393-6. [QxMD MEDLINE Link].
Gilbert DL, Bansal AS, Sethuraman G, et al. Association of cortical disinhibition with tic, ADHD, and OCD severity in Tourette syndrome. Mov Disord. 2004 Apr. 19(4):416-25. [QxMD MEDLINE Link].
Gilbert DL, Sallee FR, Zhang J, et al. Transcranial magnetic stimulation-evoked cortical inhibition: a consistent marker of attention-deficit/hyperactivity disorder scores in tourette syndrome. Biol Psychiatry. 2005 Jun 15. 57(12):1597-600. [QxMD MEDLINE Link].
Orth M, Amann B, Robertson MM, et al. Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain. 2005 Jun. 128(Pt 6):1292-300. [QxMD MEDLINE Link].
Como PG. Neuropsychological function in Tourette syndrome. Adv Neurol. 2001. 85:103-11. [QxMD MEDLINE Link].
Keri S, Szlobodnyik C, Benedek G, et al. Probabilistic classification learning in Tourette syndrome. Neuropsychologia. 2002. 40(8):1356-62. [QxMD MEDLINE Link].
Marsh R, Alexander GM, Packard MG, et al. Habit learning in Tourette syndrome: a translational neuroscience approach to a developmental psychopathology. Arch Gen Psychiatry. 2004 Dec. 61(12):1259-68. [QxMD MEDLINE Link].
Marsh R, Alexander GM, Packard MG, et al. Perceptual-motor skill learning in Gilles de la Tourette syndrome. Evidence for multiple procedural learning and memory systems. Neuropsychologia. 2005. 43(10):1456-65. [QxMD MEDLINE Link].
LeVasseur AL, Flanagan JR, Riopelle RJ, Munoz DP. Control of volitional and reflexive saccades in Tourette''s syndrome. Brain. 2001 Oct. 124(Pt 10):2045-58. [QxMD MEDLINE Link].
Leckman JF, Katsovich L, Kawikova I, et al. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette's syndrome. Biol Psychiatry. 2005 Mar 15. 57(6):667-73. [QxMD MEDLINE Link].
Tang Y, Gilbert DL, Glauser TA, et al. Blood gene expression profiling of neurologic diseases: a pilot microarray study. Arch Neurol. 2005 Feb. 62(2):210-5. [QxMD MEDLINE Link].
Hong JJ, Loiselle CR, Yoon DY, et al. Microarray analysis in Tourette syndrome postmortem putamen. J Neurol Sci. 2004 Oct 15. 225(1-2):57-64. [QxMD MEDLINE Link].
Alexander GM, Peterson BS. Testing the prenatal hormone hypothesis of tic-related disorders: gender identity and gender role behavior. Dev Psychopathol. 2004. 16(2):407-20. [QxMD MEDLINE Link].
Peterson BS, Leckman JF. The temporal dynamics of tics in Gilles de la Tourette syndrome. Biol Psychiatry. 1998 Dec 15. 44(12):1337-48. [QxMD MEDLINE Link].
Jankovic J. Stereotypies. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Boston: Mass. Butterworth-Heinemann. 1994:503-17.
Mink JW. Basal ganglia dysfunction in Tourette''s syndrome: a new hypothesis. Pediatr Neurol. 2001 Sep. 25(3):190-8. [QxMD MEDLINE Link].
Mink JW. Neurobiology of basal ganglia circuits in Tourette syndrome: faulty inhibition of unwanted motor patterns?. Adv Neurol. 2001. 85:113-22. [QxMD MEDLINE Link].
Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol. 1996 Nov. 50(4):381-425. [QxMD MEDLINE Link].
Flaherty AW, Graybiel AM. Input-output organization of the sensorimotor striatum in the squirrel monkey. J Neurosci. 1994 Feb. 14(2):599-610. [QxMD MEDLINE Link].
Price RA, Kidd KK, Cohen DJ, et al. A twin study of Tourette syndrome. Arch Gen Psychiatry. 1985 Aug. 42(8):815-20. [QxMD MEDLINE Link].
Devor EJ. Untying the gordian knot: the genetics of Tourette syndrome. J Nerv Ment Dis. 1990 Nov. 178(11):669-79. [QxMD MEDLINE Link].
Pauls DL. Issues in genetic linkage studies of Tourette syndrome. Phenotypic spectrum and genetic model parameters. Adv Neurol. 1992. 58:151-7. [QxMD MEDLINE Link].
State MW, Pauls DL, Leckman JF. Tourette''s syndrome and related disorders. Child Adolesc Psychiatr Clin N Am. 2001 Apr. 10(2):317-31, ix. [QxMD MEDLINE Link].
Pauls D. Genome scans in sibpairs and trios: new data. Presented at: 4th International Scientific Symposium on Tourette Syndrome; June 25-27, 2004; Cleveland, OH.
Crane J, Fagerness J, Osiecki L, Gunnell B, Stewart SE, Pauls DL, et al. Family-based genetic association study of DLGAP3 in Tourette Syndrome. Am J Med Genet B Neuropsychiatr Genet. 2011 Jan. 156(1):108-14. [QxMD MEDLINE Link]. [Full Text].
State MW, Greally JM, Cuker A, et al. Epigenetic abnormalities associated with a chromosome 18(q21-q22) inversion and a Gilles de la Tourette syndrome phenotype. Proc Natl Acad Sci U S A. 2003 Apr 15. 100(8):4684-9. [QxMD MEDLINE Link].
Abelson JF, Kwan KY, O'Roak BJ, et al. Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science. 2005 Oct 14. 310(5746):317-20. [QxMD MEDLINE Link].
Hyde TM, Aaronson BA, Randolph C, et al. Relationship of birth weight to the phenotypic expression of Gilles de la Tourette''s syndrome in monozygotic twins. Neurology. 1992 Mar. 42(3 Pt 1):652-8. [QxMD MEDLINE Link].
Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003 Jul. 9(7):914-20. [QxMD MEDLINE Link].
Snider LA, Swedo SE. Post-streptococcal autoimmune disorders of the central nervous system. Curr Opin Neurol. 2003 Jun. 16(3):359-65. [QxMD MEDLINE Link].
Swedo SE, Leonard HL, Rapoport JL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction. Pediatrics. 2004 Apr. 113(4):907-11. [QxMD MEDLINE Link].
Asbahr FR, Ramos RT, Negrao AB, Gentil V. Case series: increased vulnerability to obsessive-compulsive symptoms with repeated episodes of Sydenham chorea. J Am Acad Child Adolesc Psychiatry. 1999 Dec. 38(12):1522-5. [QxMD MEDLINE Link].
Mell LK, Davis RL, Owens D, et al. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. Pediatrics. 2005 Jul. 116(1):56-60. [QxMD MEDLINE Link].
Murphy TK, Benson N, Zaytoun A, et al. Progress toward analysis of D8/17 binding to B cells in children with obsessive compulsive disorder and/or chronic tic disorder. J Neuroimmunol. 2001 Nov 1. 120(1-2):146-51. [QxMD MEDLINE Link].
Church AJ, Dale RC, Lees AJ, et al. Tourette''s syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry. 2003 May. 74(5):602-7. [QxMD MEDLINE Link].
Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies in movement disorders. Pediatrics. 1993 Jul. 92(1):39-43. [QxMD MEDLINE Link].
Pavone P, Bianchini R, Parano E, et al. Anti-brain antibodies in PANDAS versus uncomplicated streptococcal infection. Pediatr Neurol. 2004 Feb. 30(2):107-10. [QxMD MEDLINE Link].
Wendlandt JT, Grus FH, Hansen BH, Singer HS. Striatal antibodies in children with Tourette''s syndrome: multivariate discriminant analysis of IgG repertoires. J Neuroimmunol. 2001 Sep 3. 119(1):106-13. [QxMD MEDLINE Link].
Kurlan R, Kaplan EL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) etiology for tics and obsessive-compulsive symptoms: hypothesis or entity? Practical considerations for the clinician. Pediatrics. 2004 Apr. 113(4):883-6. [QxMD MEDLINE Link].
Kurlan R. The PANDAS hypothesis: losing its bite?. Mov Disord. 2004 Apr. 19(4):371-4. [QxMD MEDLINE Link].
Muller N, Riedel M, Blendinger C, et al. Mycoplasma pneumoniae infection and Tourette's syndrome. Psychiatry Res. 2004 Dec 15. 129(2):119-25. [QxMD MEDLINE Link].
Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999 Oct 2. 354(9185):1153-8. [QxMD MEDLINE Link].
Loiselle CR, Lee O, Moran TH, Singer HS. Striatal microinfusion of Tourette syndrome and PANDAS sera: failure to induce behavioral changes. Mov Disord. 2004 Apr. 19(4):390-6. [QxMD MEDLINE Link].
Singer HS, Loiselle CR, Lee O, et al. Anti-basal ganglia antibodies in PANDAS. Mov Disord. 2004 Apr. 19(4):406-15. [QxMD MEDLINE Link].
Singer HS, Hong JJ, Yoon DY, et al. Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. Neurology. 2005 Dec 13. 65(11):1701-7. [QxMD MEDLINE Link].
Prevalence of diagnosed Tourette syndrome in persons aged 6-17 years - United States, 2007. MMWR Morb Mortal Wkly Rep. 2009 Jun 5. 58(21):581-5. [QxMD MEDLINE Link]. [Full Text].
Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 1: the epidemiological and prevalence studies. J Psychosom Res. 2008 Nov. 65(5):461-72. [QxMD MEDLINE Link].
Robertson MM. The prevalence and epidemiology of Gilles de la Tourette syndrome. Part 2: tentative explanations for differing prevalence figures in GTS, including the possible effects of psychopathology, aetiology, cultural differences, and differing phenotypes. J Psychosom Res. 2008 Nov. 65(5):473-86. [QxMD MEDLINE Link].
Hebebrand J, Klug B, Fimmers R, et al. Rates for tic disorders and obsessive compulsive symptomatology in families of children and adolescents with Gilles de la Tourette syndrome. J Psychiatr Res. 1997 Sep-Oct. 31(5):519-30. [QxMD MEDLINE Link].
Leckman JF. Phenomenology of tics and natural history of tic disorders. Brain Dev. 2003 Dec. 25 Suppl 1:S24-8. [QxMD MEDLINE Link].
Carter AS, O''Donnell DA, Schultz RT, et al. Social and emotional adjustment in children affected with Gilles de la Tourette''s syndrome: associations with ADHD and family functioning. Attention Deficit Hyperactivity Disorder. J Child Psychol Psychiatry. 2000 Feb. 41(2):215-23. [QxMD MEDLINE Link].
Martinez D, Slifstein M, Broft A, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab. 2003 Mar. 23(3):285-300. [QxMD MEDLINE Link].
Cath DC, Spinhoven P, Hoogduin CA, et al. Repetitive behaviors in Tourette''s syndrome and OCD with and without tics: what are the differences?. Psychiatry Res. 2001 Mar 25. 101(2):171-85. [QxMD MEDLINE Link].
Robertson MM, Gourdie A. Familial Tourette''s syndrome in a large British pedigree. Associated psychopathology, severity, and potential for linkage analysis. Br J Psychiatry. 1990 Apr. 156:515-21. [QxMD MEDLINE Link].
Cohen SC, Leckman JF, Bloch MH. Clinical assessment of Tourette syndrome and tic disorders. Neurosci Biobehav Rev. 2013 Jul. 37(6):997-1007. [QxMD MEDLINE Link]. [Full Text].
Burd L, Freeman RD, Klug MG, et al. Tourette Syndrome and learning disabilities. BMC Pediatr. 2005 Sep 1. 5:34. [QxMD MEDLINE Link].
Albin R. Neurobiology of basal ganglia and TS: neurotransmitters and neurochemistry overview. Presented at: 4th International Scientific Symposium on Tourette Syndrome;. June 25-27, 2004; Cleveland, Ohio.
Woods DW, Watson TS, Wolfe E, et al. Analyzing the influence of tic-related talk on vocal and motor tics in children with Tourette''s syndrome. J Appl Behav Anal. 2001 Fall. 34(3):353-6. [QxMD MEDLINE Link].
Meidinger AL, Miltenberger RG, Himle M, et al. An investigation of tic suppression and the rebound effect in Tourette's disorder. Behav Modif. 2005 Sep. 29(5):716-45. [QxMD MEDLINE Link].
Kwak C, Dat Vuong K, Jankovic J. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec. 18(12):1530-3. [QxMD MEDLINE Link].
Coffey BJ, Miguel EC, Biederman J, et al. Tourette''s disorder with and without obsessive-compulsive disorder in adults: are they different?. J Nerv Ment Dis. 1998 Apr. 186(4):201-6. [QxMD MEDLINE Link].
Leckman JF, Walker DE, Goodman WK, Pauls DL, Cohen DJ. "Just right" perceptions associated with compulsive behavior in Tourette's syndrome. Am J Psychiatry. 1994 May. 151(5):675-80. [QxMD MEDLINE Link].
Miguel EC, do Rosario-Campos MC, Prado HS, et al. Sensory phenomena in obsessive-compulsive disorder and Tourette''s disorder. J Clin Psychiatry. 2000 Feb. 61(2):150-6; quiz 157. [QxMD MEDLINE Link].
Scahill LD, Leckman JF, Marek KL. Sensory phenomena in Tourette''s syndrome. Adv Neurol. 1995. 65:273-80. [QxMD MEDLINE Link].
Bliss J. Sensory experiences of Gilles de la Tourette syndrome. Arch Gen Psychiatry. 1980 Dec. 37(12):1343-7. [QxMD MEDLINE Link].
Chappell P, Leckman J, Goodman W, et al. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette''s syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry. 1996 May 1. 39(9):776-83. [QxMD MEDLINE Link].
Morris HR, Thacker AJ, Newman PK, Lees AJ. Sign language tics in a prelingually deaf man. Mov Disord. 2000 Mar. 15(2):318-20. [QxMD MEDLINE Link].
Chabane N, Delorme R, Millet B, et al. Early-onset obsessive-compulsive disorder: a subgroup with a specific clinical and familial pattern?. J Child Psychol Psychiatry. 2005 Aug. 46(8):881-7. [QxMD MEDLINE Link].
do Rosario-Campos MC, Leckman JF, Curi M, et al. A family study of early-onset obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet. 2005 Jul 5. 136(1):92-7. [QxMD MEDLINE Link].
Miguel EC. Co-morbid OCD. Presented at: 4th International Scientific Symposium on Tourette Syndrome; June 25-27, 2004; Cleveland, OH.
Block MH. Presentation at: 4th International Scientific Symposium on Tourette Syndrome. June 25-27, 2004; Cleveland, OH.
Bockner S. Gilles de la Tourette''s disease. J Ment Sci. 1959 Oct. 105:1078-81. [QxMD MEDLINE Link].
Kurlan R, Trinidad KS. Treatment of tics. In: Kurlan R, ed. Treatment of Movement Disorders. Philadelphia, PA:. JB Lippincott. 1995: 365-406.
McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol. 2008 Oct. 18(5):501-8. [QxMD MEDLINE Link].
Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette''s disorder: a comparative double-blind parallel-group study. J Clin Psychiatry. 2001 Jan. 62(1):50-6. [QxMD MEDLINE Link].
Onofrj M, Paci C, D''Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol. 2000 Jun. 247(6):443-6. [QxMD MEDLINE Link].
Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette''s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000 Mar. 39(3):292-9. [QxMD MEDLINE Link].
Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979 Mar. 136(3):317-20. [QxMD MEDLINE Link].
Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol. 2005 Sep. 8(3):489-90. [QxMD MEDLINE Link].
Seo WS, Sung HM, Sea HS, Bai DS. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol. 2008 Apr. 18(2):197-205. [QxMD MEDLINE Link].
Acosta MT, Castellanos FX. Use of the "inverse neuroleptic" metoclopramide in Tourette syndrome: an open case series. J Child Adolesc Psychopharmacol. 2004 Spring. 14(1):123-8. [QxMD MEDLINE Link].
Nicolson R, Craven-Thuss B, Smith J, et al. A randomized, double-blind, placebo-controlled trial of metoclopramide for the treatment of Tourette's disorder. J Am Acad Child Adolesc Psychiatry. 2005 Jul. 44(7):640-6. [QxMD MEDLINE Link].
Gilbert DL, Sethuraman G, Sine L, et al. Tourette''s syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology. 2000 Mar 28. 54(6):1310-5. [QxMD MEDLINE Link].
Azrin NH, Nunn RG, Frantz SE. Habit reversal vs. negative practice treatment of nervous tics. Behav Res Ther. 1980. 11:169-78.
Azrin NH, Peterson AL. Habit reversal for the treatment of Tourette syndrome. Behav Res Ther. 1988. 26(4):347-51. [QxMD MEDLINE Link].
Wilhelm S, Deckersbach T, Coffey BJ, et al. Habit reversal versus supportive psychotherapy for Tourette''s disorder: a randomized controlled trial. Am J Psychiatry. 2003 Jun. 160(6):1175-7. [QxMD MEDLINE Link].
Deckersbach T, Rauch S, Buhlmann U, et al. Habit reversal versus supportive psychotherapy in Tourette's disorder: A randomized controlled trial and predictors of treatment response. Behav Res Ther. 2005 Oct 28. [QxMD MEDLINE Link].
Dutta N, Cavanna AE. The effectiveness of habit reversal therapy in the treatment of Tourette syndrome and other chronic tic disorders: a systematic review. Funct Neurol. 2013 Jan-Mar. 28(1):7-12. [QxMD MEDLINE Link].
Black KJ. Habit Reversal Therapy for Tourette Syndrome. Available at http://www.nil.wustl.edu/labs/kevin/move/HRT.htm. Accessed: August 31, 2009.
Miltenberger RG, Fuqua RW, Woods DW. Applying behavior analysis to clinical problems: review and analysis of habit reversal. J Appl Behav Anal. 1998 Fall. 31(3):447-69. [QxMD MEDLINE Link].
Jenkins BG, Chen YI, Sanchez Pernaute R, et al. Mapping dopaminergic function in normal and MPTP treated monkeys with pharmacologic MRI and PET. Presented at: Annual Meeting of the Society of Neuroscience; November 10-15, 2001; San Diego, CA.
Woods DW, Hook SS, Spellman DF, Friman PC. Case study: Exposure and response prevention for an adolescent with Tourette''s syndrome and OCD. J Am Acad Child Adolesc Psychiatry. 2000 Jul. 39(7):904-7. [QxMD MEDLINE Link].
Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001 Jul. 158(7):1067-74. [QxMD MEDLINE Link].
The Tourette''s Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002 Feb 26. 58(4):527-36. [QxMD MEDLINE Link].
Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psych. 2010 Jan. 81(1):70-3.
Yang CS, Zhang LL, Zeng LN et al. Topiramate for Tourette's syndrome in children: a meta-analysis. Ped Neurol. 2013 Nov. 49(5):344-50.
Spencer T, Biederman J, Coffey B, et al. A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2002 Jul. 59(7):649-56. [QxMD MEDLINE Link].
Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005 Dec 27. 65(12):1941-9. [QxMD MEDLINE Link].
Marras C, Andrews D, Sime E, Lang AE. Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial. Neurology. 2001 Mar 13. 56(5):605-10. [QxMD MEDLINE Link].
Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb. 48(2):358-62. [QxMD MEDLINE Link].
U.S. Food and Drug Administration. FDA Approves First Drug for Treatment of Chorea in Huntington's Disease. FDA. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116936.htm. Accessed: August 31, 2009.
Singer HS, Wendlandt J, Krieger M, Giuliano J. Baclofen treatment in Tourette syndrome: a double-blind, placebo-controlled, crossover trial. Neurology. 2001 Mar 13. 56(5):599-604. [QxMD MEDLINE Link].
Awaad Y, Michon AM, Minarik S, et al. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome. Mov Disord. 2005 Jun. 20(6):714-8. [QxMD MEDLINE Link].
Hedderick EF, Morris CM, Singer HS. Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol. 2009 Jun. 40(6):420-5. [QxMD MEDLINE Link].
Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS. A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord. 2007 Sep 15. 22(12):1764-70. [QxMD MEDLINE Link].
Bruun RD, Budman CL. Paroxetine treatment of episodic rages associated with Tourette''s disorder. J Clin Psychiatry. 1998 Nov. 59(11):581-4. [QxMD MEDLINE Link].
Iancu I, Kotler M, Bleich A, Lepkifker E. Clomipramine efficacy for Tourette syndrome and major depression: a case study. Biol Psychiatry. 1995 Sep 15. 38(6):407-9. [QxMD MEDLINE Link].
Kurlan R, Como PG, Deeley C, et al. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette''s syndrome. Clin Neuropharmacol. 1993 Apr. 16(2):167-72. [QxMD MEDLINE Link].
Scahill L, Riddle MA, King RA, et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette''s syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol. 1997 Summer. 7(2):75-85. [QxMD MEDLINE Link].
Chappell PB, Leckman JF, Riddle MA, et al. Neuroendocrine and behavioral effects of naloxone in Tourette syndrome. Adv Neurol. 1992. 58:253-62. [QxMD MEDLINE Link].
Erenberg G, Lederman RJ. Naltrexone and Tourette''s syndrome. Ann Neurol. 1992 May. 31(5):574. [QxMD MEDLINE Link].
van Wattum PJ, Chappell PB, Zelterman D, et al. Patterns of response to acute naloxone infusion in Tourette''s syndrome. Mov Disord. 2000 Nov. 15(6):1252-4. [QxMD MEDLINE Link].
Chappell PB, Leckman JF, Scahill LD, et al. Neuroendocrine and behavioral effects of the selective kappa agonist spiradoline in Tourette''s syndrome: a pilot study. Psychiatry Res. 1993 Jun. 47(3):267-80. [QxMD MEDLINE Link].
McConville BJ, Norman AB, Fogelson MH, Erenberg G. Sequential use of opioid antagonists and agonists in Tourette''s syndrome. Lancet. 1994 Mar 5. 343(8897):601. [QxMD MEDLINE Link].
Silver AA, Shytle RD, Philipp MK, et al. Transdermal nicotine and haloperidol in Tourette''s disorder: a double-blind placebo-controlled study. J Clin Psychiatry. 2001 Sep. 62(9):707-14. [QxMD MEDLINE Link].
Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR. Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder. J Am Acad Child Adolesc Psychiatry. 2001 Sep. 40(9):1103-10. [QxMD MEDLINE Link].
Orth M, Kirby R, Richardson MP, et al. Subthreshold rTMS over pre-motor cortex has no effect on tics in patients with Gilles de la Tourette syndrome. Clin Neurophysiol. 2005 Apr. 116(4):764-8. [QxMD MEDLINE Link].
Hembree EA, Riggs DS, Kozak MJ, et al. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectr. 2003 May. 8(5):363-71, 381. [QxMD MEDLINE Link].
McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994 Apr. 51(4):302-8. [QxMD MEDLINE Link].
Miguel EC, Shavitt RG, Ferrao YA, et al. How to treat OCD in patients with Tourette syndrome. J Psychosom Res. 2003 Jul. 55(1):49-57. [QxMD MEDLINE Link].
Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette''s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry. 1997 May. 36(5):589-96. [QxMD MEDLINE Link].
Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics. 1999 Aug. 104(2):e20. [QxMD MEDLINE Link].
Kurlan R. Tourette''s syndrome: are stimulants safe?. Curr Neurol Neurosci Rep. 2003 Jul. 3(4):285-8. [QxMD MEDLINE Link].
Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings. J Am Acad Child Adolesc Psychiatry. 1992 May. 31(3):462-71. [QxMD MEDLINE Link].
Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry. 1999 Apr. 56(4):330-6. [QxMD MEDLINE Link].
Sverd J, Gadow KD, Paolicelli LM. Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette''s syndrome. J Am Acad Child Adolesc Psychiatry. 1989 Jul. 28(4):574-9; discussion 580-2. [QxMD MEDLINE Link].
Feigin A, Kurlan R, McDermott MP, et al. A controlled trial of deprenyl in children with Tourette''s syndrome and attention deficit hyperactivity disorder. Neurology. 1996 Apr. 46(4):965-8. [QxMD MEDLINE Link].
Spencer T, Biederman J, Steingard R, Wilens T. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette''s syndrome. J Am Acad Child Adolesc Psychiatry. 1993 Jan. 32(1):211-4. [QxMD MEDLINE Link].
Donovan SJ, Stewart JW, Nunes EV, et al. Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry. 2000 May. 157(5):818-20. [QxMD MEDLINE Link].
Budman C, Coffey BJ, Shechter R, Schrock M, Wieland N, Spirgel A, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol. 2008 Oct. 18(5):509-15. [QxMD MEDLINE Link].
Ackermans L, Duits A, van der Linden C, et al. Double-blind clinical trial of thalamic stimulation in patients with Tourette syndrome. Brain. 2011 Mar. 134:832-44. [QxMD MEDLINE Link].
Woods DW, Marcks BA. Controlled evaluation of an educational intervention used to modify peer attitudes and behavior toward persons with Tourette's Syndrome. Behav Modif. 2005 Nov. 29(6):900-12. [QxMD MEDLINE Link].
Pringsheim T, Okun MS, Müller-Vahl K, Martino D, Jankovic J, Cavanna AE, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019 May 7. 92 (19):896-906. [QxMD MEDLINE Link].
Brauser D. Potential New Risk Factors for Tourette's, Tics Identified. Available at http://www.medscape.com/viewarticle/819287. Accessed: January 19, 2014.
Mathews CA, Scharf JM, Miller LL, Macdonald-Wallis C, Lawlor DA, Ben-Shlomo Y. Association between pre- and perinatal exposures and Tourette syndrome or chronic tic disorder in the ALSPAC cohort. Br J Psychiatry. 2014 Jan. 204:40-5. [QxMD MEDLINE Link]. [Full Text].
